Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resolaris extension in FSHD
NCT02531217Phase 2Completed
- Sponsor
- aTyr Pharma
- Start
- Aug 2015
- Primary completion
- May 2016
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 3
01
Overview
A Phase 2 trial of Resolaris in facioscapulohumeral muscular dystrophy (FSHD), sponsored by aTyr Pharma. Started Aug 2015; status: completed.
02
Drugs
Resolaris
03
Conditions
facioscapulohumeral muscular dystrophy (FSHD)
Beyond the preview
Go deeper on NCT02531217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02531217.